GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

GlobeStar Therapeutics GSTC · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Popular Bitcoin Ethereum Nvidia Apple S&P 500 Gold EUR/USD US 10Y

At a glance

Figures in USD, from our data supplier.

FY2023

Revenue

—

FY2016FY2023

Net income

−$1.9m

FY2016FY2023

Free cash flow

−$205,800

FY2016FY2023

Shareholders' equity

−$1.4m

FY2016FY2023

Income statement

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue———$100$400$900——
Gross profit——−$2,400−$37,600$300$700——
Operating income−$1.9m−$1.3m−$9.1m−$303,700−$315,900−$351,000−$460,900−$155,500
Net income−$1.9m−$1.5m−$9.8m−$541,700−$2.3m−$816,700−$1.7m−$3.5m
Diluted earnings per share-0.00-0.00-0.02-0.00-0.02-0.01-0.04-0.13

Balance sheet

At each fiscal year end

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets—$9,900$6,000$89,900$142,200$124,800$24,600$17,300
Cash and short-term investments—$6,400$6,000$81,400$100,500$91,600$14,100$5,900
Total liabilities$1.4m$1.2m$731,800$749,100$827,600$995,500$648,500$860,400
Debt$359,700$20,000$20,000$155,100$113,800$285,300$88,800$522,700
Shareholders' equity−$1.4m−$1.2m−$725,800−$659,200−$685,400−$870,700−$624,000−$843,100
Shares outstanding827m629m482m298m105m57m39m27m

Cash flow

Fiscal years

FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−$205,800−$327,000−$751,200−$239,700−$260,100−$180,100−$53,800−$30,000
Capital spending———−$1,800—−$1,400——
Free cash flow−$205,800−$327,000−$751,200−$241,500−$260,100−$181,500−$53,800−$30,000

Latest quarters

By quarter end

Sept 2023Jun 2023Mar 2023Dec 2022Sept 2022Jun 2022Mar 2022Dec 2021
Operating income−$287,800−$1.3m−$142,100−$155,200−$299,800−$136,600−$662,300−$166,300
Net income−$350,600−$1.3m−$150,200−$165,900−$308,300−$158,100−$688,600−$332,800
Diluted earnings per share-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00
Total assets——$200$10,200——$600$25,200
Cash and short-term investments——$200$7,700——$600$21,400
Debt$300,000———————
Shareholders' equity−$1.4m−$1.3m−$1.3m−$1.2m—−$966,500−$1.1m−$897,200

Growth per year

Compound annual rate

3 years5 years10 years
Operating income83.1%39.7%—
Net income53.2%19.0%—

Valuation history

At each fiscal year end

FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-0.1-0.9-0.1-0.7-0.0-0.4-0.0
Price to sales————137.0339.1—

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-20%-33%-89%-6%65%97%-73%107%152%1%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 100-to-1 reverse split · 30 Jun 2015
  • 20-to-1 reverse split · 17 Aug 2012

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.